Qiong Du

954 total citations
53 papers, 655 citations indexed

About

Qiong Du is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Qiong Du has authored 53 papers receiving a total of 655 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 15 papers in Molecular Biology and 9 papers in Cancer Research. Recurrent topics in Qiong Du's work include HER2/EGFR in Cancer Research (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Qiong Du is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Qiong Du collaborates with scholars based in China, Japan and United States. Qiong Du's co-authors include Qing Zhai, Bin Zhu, Xuan Ye, Bo Yu, Bo Yu, Huan Li, Hongyue Liu, Jiyong Liu, Huan Li and Xin Luo and has published in prestigious journals such as Chemosphere, Frontiers in Immunology and Oncotarget.

In The Last Decade

Qiong Du

48 papers receiving 648 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qiong Du China 15 288 223 124 81 69 53 655
Yue Qiu China 16 404 1.4× 215 1.0× 78 0.6× 118 1.5× 55 0.8× 57 690
Jia Fei China 17 429 1.5× 194 0.9× 99 0.8× 53 0.7× 55 0.8× 55 884
Binghui Li China 19 596 2.1× 445 2.0× 131 1.1× 99 1.2× 56 0.8× 44 1.0k
Kensuke Mitsunari Japan 13 289 1.0× 112 0.5× 103 0.8× 137 1.7× 46 0.7× 68 677
Tatiane De Rossi Brazil 7 179 0.6× 88 0.4× 118 1.0× 42 0.5× 30 0.4× 11 440
Shiyu Du China 11 334 1.2× 175 0.8× 200 1.6× 121 1.5× 87 1.3× 33 838
Davar Amani Iran 18 477 1.7× 287 1.3× 183 1.5× 65 0.8× 80 1.2× 72 985
Zhihua Xu China 17 451 1.6× 256 1.1× 185 1.5× 92 1.1× 38 0.6× 53 719
Chao Deng China 13 277 1.0× 144 0.6× 100 0.8× 39 0.5× 80 1.2× 38 551

Countries citing papers authored by Qiong Du

Since Specialization
Citations

This map shows the geographic impact of Qiong Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qiong Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qiong Du more than expected).

Fields of papers citing papers by Qiong Du

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qiong Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qiong Du. The network helps show where Qiong Du may publish in the future.

Co-authorship network of co-authors of Qiong Du

This figure shows the co-authorship network connecting the top 25 collaborators of Qiong Du. A scholar is included among the top collaborators of Qiong Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qiong Du. Qiong Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tong, Xuhui, Rong Tang, Jin Xu, et al.. (2025). Cancer type-specific adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis. Heliyon. 11(1). e41597–e41597.
2.
Luo, Jiefeng, et al.. (2025). Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma. Human Vaccines & Immunotherapeutics. 21(1). 2582294–2582294.
3.
4.
5.
Wang, Mengmeng, et al.. (2024). Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study. Pharmaceuticals. 17(8). 1025–1025. 5 indexed citations
6.
7.
Wang, Mengmeng, et al.. (2024). Efficacy and Safety of Bevacizumab Biosimilar (Encoda) Compared With Reference Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer: A Multicenter, Real-World Study. Clinical Medicine Insights Oncology. 18. 1383424686–1383424686. 4 indexed citations
8.
Liu, Wensheng, et al.. (2023). Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database. Frontiers in Pharmacology. 14. 1283247–1283247. 17 indexed citations
9.
Tang, Rong, Jin Xu, Wei Wang, et al.. (2023). Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Cell Reports Medicine. 4(10). 101234–101234. 31 indexed citations
10.
11.
Zhang, Ping, Bin Zhao, Qiong Du, et al.. (2022). Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years. Frontiers in Immunology. 13. 778635–778635. 8 indexed citations
12.
Du, Qiong, Xuan Ye, Huan Li, et al.. (2021). Exosomal miR-30a and miR-222 derived from colon cancer mesenchymal stem cells promote the tumorigenicity of colon cancer through targeting MIA3. Journal of Gastrointestinal Oncology. 12(1). 52–68. 39 indexed citations
13.
Liu, Hongyue, Qiong Du, Hui Zhang, et al.. (2021). Efficacy and safety of domestic and imported gefitinib in patients with advanced non-small cell lung cancer. Annals of Palliative Medicine. 10(1). 10–15. 5 indexed citations
14.
Ye, Xuan, Xin Luo, Qiong Du, et al.. (2020). Efficacy and safety of lapatinib in Chinese breast cancer patients: a real-world study. Annals of Translational Medicine. 8(5). 240–240. 3 indexed citations
15.
Wang, Yuan, et al.. (2019). Performance and mechanism of Cr(VI) removal by resin-supported nanoscale zero-valent iron (nZVI): role of nZVI distribution. Desalination and Water Treatment. 166. 344–352. 2 indexed citations
16.
Zhai, Qing, et al.. (2017). Neutropenic complications in Chinese patients with breast cancer in a real-world setting. International Journal of Clinical and Experimental Pathology. 10(1). 651–660. 4 indexed citations
17.
Ye, Xuan, Qiong Du, Huan Li, Bo Yu, & Qing Zhai. (2016). Calcium Channel Blockers and Risk of Breast Cancer: A meta-Analysis. 9(10). 20425–20431. 2 indexed citations
18.
Du, Qiong, et al.. (2013). Role of mitochondrial permeability transition in human hepatocellular carcinoma Hep-G2 cell death induced by rhein. Fitoterapia. 91. 68–73. 44 indexed citations
19.
Du, Qiong, et al.. (2010). The Thinking of Economic Transformation and the Predicament of Resource Exhaustion in Kunming Dongchuan Areas. Yunnan Nongye Daxue xuebao. 4(3). 74–78. 1 indexed citations
20.
Du, Qiong. (2006). Correlation between high affinity immunoglobulin E receptor gene and asthmatic children in Sichuan of China. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yue Qiu Breakdown of academic impact, for papers by Jia Fei Breakdown of academic impact, for papers by Binghui Li Breakdown of academic impact, for papers by Kensuke Mitsunari Breakdown of academic impact, for papers by Tatiane De Rossi Breakdown of academic impact, for papers by Shiyu Du Breakdown of academic impact, for papers by Davar Amani Breakdown of academic impact, for papers by Zhihua Xu Breakdown of academic impact, for papers by Chao Deng
Rankless by CCL
2026